EPDR1 is related to stages and metastasize in bladder cancer and can be used as a prognostic biomarker

8Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Bladder cancer (BLCA) is a malignant urothelial carcinoma and has a high mortality rate. EPDR1 (ependymin related 1) is a type II transmembrane protein and related to calcium-dependent cell adhesion. Methods: We explored the potential oncogenic roles of EPDR1 in BLCA basing on the multiple public datasets. Results: We found that EPDR1 expression had a significant difference in BLCA and adjacent normal bladder tissues, and the level of EPDR1was up-regulated with advanced tumor stage and metastasis in BLCA. Meanwhile, the high expression group of EPDR1 had a shorter OS compared to the low or medium expression-group. Furthermore, EPDR1 expression was associated with tumor-infiltrating immune cells (TIICs), including NK cells, CD8 + T cells, CD4 + T cells, Macrophages cells, and so on. Moreover, EPDR1 also involved in several signaling pathways as well as PI3K/AKT pathway, Cytokine receptor interaction, and apoptosis. Conclusion: EPDR1 can be used as a novel prognostic biomarker as well as an effective target for diagnosis and treatment in BLCA.

Cite

CITATION STYLE

APA

Yang, Y., Zhang, H., Liu, Z., Zhao, F., & Liang, G. (2021). EPDR1 is related to stages and metastasize in bladder cancer and can be used as a prognostic biomarker. BMC Urology, 21(1). https://doi.org/10.1186/s12894-021-00843-2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free